Araris Biotech
Araris Biotech AG is a spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich pioneering a novel antibody-drug conjugate (ADC)-linker technology. Their linker platform enables the attachment of any payload to ‘off the shelf’ antibodies without the need of prior antibody engineering.
Building tomorrow's antibody-drug conjugates
Get to know Araris Biotech
Headquartered in: Zurich, Switzerland
Founded in: 2019
Sector: Biotechnology, Medtech
Investor: Managed Partner Funds